Overview

This trial has been completed.

Condition glaucoma
Treatment smartphone application
Sponsor Wills Eye
Start date June 2015
End date October 2016
Trial size 100 participants
Trial identifier NCT02659709, 14-413E

Summary

Develop smartphone- and tablet-based application (app) for participants with glaucoma, ocular hypertension and those at risk.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose health services research
Arm
(Other)
Glaucoma patients will test a glaucoma smartphone application (app) on smart phones or tablets then complete 20 item questionnaire providing demographic information, effectiveness and ease of use with the application.
smartphone application Glaucoma App
Smartphone Application designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.

Primary Outcomes

Measure
Smartphone Usage Questionnaire
time frame: 1 day

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Anyone affected by glaucoma, this includes people with the disease, family and friends of someone with the disease. Exclusion Criteria:

Additional Information

Official title A Smartphone- and Tablet-Based Application for Patients With Glaucoma
Principal investigator Jonathan S Myers, MD
Description The Investigators are developing a smartphone and tablet-based application (App) for participants with glaucoma. The purpose of this App is to enhance understanding of glaucoma by using short video tutorials. The App will also include glaucoma eye drop medication reminders, a short video tutorial that aims to improve understanding of how visual field testing should be performed correctly, and a feature that will enable participants to store and organize testing results using a mobile device.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Wills Eye.